Filtered By:
Condition: Headache
Management: Centers for Disease Control and Prevention (CDC)
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 34 results found since Jan 2013.
How to Tell The Difference Between Heat Stress, Exhaustion, and Stroke
The terminology around heat injuries and illness is often confusing. As extreme heat warnings sweep the U.S., here is what you need to know about heat stress, heat exhaustion, and heat stroke.
A 90°F-day might be perfect for the beach. But once you start working your body, whether it’s mowing the lawn, going for a hike, or sprinting to catch the bus, your metabolism ramps up, burning fuel and raising your body’s core temperature. Your heart compensates by pumping blood away from your overheated organs to your skin, where dilating blood vessels can dissipate the heat with the help of evaporating sweat. If yo...
Source: TIME: Health - July 18, 2023 Category: Consumer Health News Authors: Aryn Baker Tags: Uncategorized Climate Is Everything Explainer extreme weather healthscienceclimate Source Type: news
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit using...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in ...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Madison Small And The Threat Of Bacterial Meningitis
Eighteen-year old high school student Madison Small of Ashburn, Virginia is dead after a swift and unexpected bacterial infection, reported ABC News. Small, an accomplished softball player, complained of a headache on the evening of Monday, Apr. 6 and was taken to the hospital, according to local news station WJLA in the video above. She died the next morning.
On April 13, health investigators announced that she had died of bacterial meningitis, but said that her case was not part of a wider outbreak in the community.
Bacterial meningitis is rare but severe. The infection, which can be caused by several different strai...
Source: Science - The Huffington Post - April 13, 2015 Category: Science Source Type: news
Depression in the Elderly: A Common Condition That's Often Overlooked
When Suzette Santos, RN, a behavioral health nurse with the Visiting Nurse Service of New York (VNSNY), was assigned to the case of Grace*, an 89-year-old resident of Nassau County on Long Island, she had some idea what to expect. Suzette had cared for Grace a year earlier, as the elderly woman struggled to cope with depression brought on by the recent loss of her husband and lifelong partner. When Suzette reconnected with her patient this time, she could immediately see that Grace's depression had gotten worse. "She had lost a lot of weight -- about 20 pounds," Suzette recalls. "She had no interest in cooking or eating, ...
Source: Healthy Living - The Huffington Post - December 23, 2015 Category: Consumer Health News Source Type: news
Don’t shrug off shingles
If you had chickenpox as a kid, there is a good chance you may develop shingles later in life. “In fact, one in three is predicted to get shingles during their lifetime,” says Dr. Anne Louise Oaklander, director of the Nerve Unit at Harvard-affiliated Massachusetts General Hospital.
The same varicella-zoster virus that causes chickenpox also causes shingles. After the telltale spots of chickenpox vanish, the virus lies dormant in your nerve cells near the spinal cord and brain. When your immunity weakens from normal aging or from illnesses or medications, the virus can re-emerge. It then travels along a nerve to trigge...
Source: New Harvard Health Information - February 18, 2016 Category: Consumer Health News Authors: Matthew Solan Tags: Healthy Aging Infectious diseases Vaccines Source Type: news
After Natural Disasters, Risk of Death and Injury Rises
ATLANTA (AP) — Irma's deadly rampage is over but authorities say the risk of deaths and injuries rises significantly after natural disasters. The U.S. Centers for Disease Control and Prevention says all kinds of hazards can endanger storm survivors, returning evacuees, emergency responders and cleanup crews. "The aftermath of disasters such as Hurricanes Harvey and Irma can be just as dangerous as the storms themselves," notes CDC Director Brenda Fitzgerald. And Orlando Fire Department Lt. Aaron Rhodes, notes stress and fatigue can lead to trouble after a disaster: "For one, people get tired, people get fr...
Source: JEMS Patient Care - September 14, 2017 Category: Emergency Medicine Authors: Associated Press Tags: Major Incidents Patient Care News Source Type: news
Evidence-Based Contraception: Common Questions and Answers
Am Fam Physician. 2022 Sep;106(3):251-259.ABSTRACTPrimary care clinicians are uniquely situated to reduce unintended pregnancy in the context of a patient's medical comorbidities, social circumstance, and gender identity. New evidence regarding contraception use has emerged in recent years. The copper intrauterine device is the most effective option for emergency contraception, with similar effectiveness found for the levonorgestrel-releasing intrauterine system, 52 mg, and both offer extended future contraception. Ulipristal given within 120 hours after unprotected intercourse is the most effective oral emergency contrace...
Source: American Family Physician - September 20, 2022 Category: Primary Care Authors: Scott L Paradise Corinne A Landis David A Klein Source Type: research
